BACKGROUND: Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases. METHODS: Patients (n= 172) undergoing operations for neuroendocrine liver metastases from any primary were identified from a prospective liver database. Recorded data and medical record review were used to analyse the type of procedure, length of hospital stay, peri-operative morbidity, tumour recurrence, progression,and survival. RESULTS: The median age was 56.8 years (range 11.5-80.7 years). 48.3% of patients were female. Median overall survival was 9.6 years (range 89 days to 22 years). On multivariate analysis, lung/thymic primaries were associated with worse survival [hazard ratio (HR): 15.6, confidence interval (CI): 4.3-56.8, P= 0.002]. Severe post-operative complications were also associated with worse long-term survival (P < 0.001). A positive resection margin status (R1) was not associated with a worse overall survival probability (P approximately 0.8). DISCUSSION: Early and aggressive surgical management of hepatic metastases from neuroendocrine tumours is associated with significant long-term survival rates. Radiofrequency ablation is a reasonable option if a lesion is unresectable. R1 resections, unlike many other cancers, are not associated with a worse overall survival.
BACKGROUND: Surgical cytoreduction and endocrine blockade are important options for care for neuroendocrine liver metastases. We investigated the long-term survival of patients surgically treated for hepatic neuroendocrine metastases. METHODS:Patients (n= 172) undergoing operations for neuroendocrine liver metastases from any primary were identified from a prospective liver database. Recorded data and medical record review were used to analyse the type of procedure, length of hospital stay, peri-operative morbidity, tumour recurrence, progression,and survival. RESULTS: The median age was 56.8 years (range 11.5-80.7 years). 48.3% of patients were female. Median overall survival was 9.6 years (range 89 days to 22 years). On multivariate analysis, lung/thymic primaries were associated with worse survival [hazard ratio (HR): 15.6, confidence interval (CI): 4.3-56.8, P= 0.002]. Severe post-operative complications were also associated with worse long-term survival (P < 0.001). A positive resection margin status (R1) was not associated with a worse overall survival probability (P approximately 0.8). DISCUSSION: Early and aggressive surgical management of hepatic metastases from neuroendocrine tumours is associated with significant long-term survival rates. Radiofrequency ablation is a reasonable option if a lesion is unresectable. R1 resections, unlike many other cancers, are not associated with a worse overall survival.
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Susan C Pitt; Jaime Knuth; James M Keily; John C McDermott; Sharon M Weber; Hebert Chen; William S Rilling; Edward J Quebbeman; David M Agarwal; Henry A Pitt Journal: J Gastrointest Surg Date: 2008-08-16 Impact factor: 3.452
Authors: A Ahmed; G Turner; B King; L Jones; D Culliford; D McCance; J Ardill; B T Johnston; G Poston; M Rees; M Buxton-Thomas; M Caplin; J K Ramage Journal: Endocr Relat Cancer Date: 2009-05-20 Impact factor: 5.678
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Matthew H G Katz; Huamin Wang; Jason B Fleming; Charlotte C Sun; Rosa F Hwang; Robert A Wolff; Gauri Varadhachary; James L Abbruzzese; Christopher H Crane; Sunil Krishnan; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans Journal: Ann Surg Oncol Date: 2009-02-05 Impact factor: 5.344
Authors: James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier Journal: Pancreas Date: 2020-01 Impact factor: 3.327
Authors: Jill K Onesti; Lawrence A Shirley; Neil D Saunders; Gail W Davidson; Mary E Dillhoff; Hooman Khabiri; Gregory E Guy; Joshua D Dowell; Carl R Schmidt; Manisha H Shah; Mark Bloomston Journal: J Gastrointest Surg Date: 2015-10-21 Impact factor: 3.452
Authors: Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik Journal: J Am Coll Surg Date: 2012-10-11 Impact factor: 6.113